Renibus Therapeutics Announces Presentations at the American Society of Nephrology Kidney Week 2020

DALLAS, Texas, Oct. 19, 2020 (GLOBE NEWSWIRE) -- Renibus Therapeutics, Inc., a clinical-stage biotechnology company, announced today that it will present five abstracts at the American Society of Nephrology (ASN) Kidney Week 2020, which is being held virtually from October 22-25, 2020. The abstracts will highlight clinical and nonclinical data from novel drug formulations being developed for the treatment of chronic kidney disease (CKD), acute kidney injury (AKI), and COVID-19.

The selected abstracts will be presented as ePosters and will be available for viewing on-demand beginning October 22 at 10:00am (EDT).

Abstract Presentations:

1. **Design of START: A Phase 2 Study Evaluating the Safety and Efficacy of RBT-1 on Preconditioning Response Biomarkers in Subjects Undergoing Cardiac Surgery**
   - ePoster #: PO0099
   - Session: AKI Clinical, Outcomes, and Trials - 1

2. **Biomarker and Safety Results from a Phase 1b Study of RBT-9 in Healthy Volunteers and Subjects with CKD Stage 3/4**
   - ePoster #: PO0066
   - Session: AKI Clinical, Outcomes, and Trials – 1

3. **Design of PREVENT: A Phase 2 Study of the Effect of RBT-9 on Progression of COVID-19 Infection in High Risk Individuals, Including Those With Advanced Chronic Kidney Disease**
   - ePoster #: PO0863
   - Session: COVID-19: Clinical and Basic Science Characteristics

4. **A Novel, Fast-Acting Iron Sucrose Formulation for CKD Patients with Iron Deficiency Anemia**
   - ePoster #: PO0283
   - Session: Anemia and Iron Management

5. **A Pharmacologic Stress Test for Assessing Select Antioxidant Defenses in Patients with CKD**
   - ePoster #: PO2359
   - Session: Pharmacology (PharmacoKinetics, -Dynamics, -Genomics)

About Renibus Therapeutics, Inc.

Renibus Therapeutics is a clinical-stage biotechnology company developing novel therapies for kidney diseases. The Company’s portfolio includes RBT-1 for prevention of acute kidney injury, RBT-2 for delaying progression of chronic kidney disease (CKD), RBT-3 for the treatment of iron deficiency anemia, RBT-6 for pharmacologic stress testing in kidney diseases, and RBT-9 for the treatment of COVID-19 and other viral diseases.

Disclaimer

This article contains information regarding our future discovery, development efforts, business strategy, and market opportunities. This information constitutes a forward-looking statement. There are a number of risks and uncertainties that could cause our actual results to differ materially from those indicated by such forward-looking statements. These risks and uncertainties include those inherent in pharmaceutical research, such as adverse results in our drug discovery and clinical development processes, decisions made by the FDA and other regulatory authorities, market conditions, our ability to obtain, maintain and enforce proprietary rights and our ability to obtain any necessary financing to conduct our planned activities.

For more information, please visit the Company’s website at [www.renibus.com](http://www.renibus.com).

Media contact: renibus@edelman.com